MCID: BNM001
MIFTS: 60

Bone Marrow Cancer

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Bone Marrow Cancer

MalaCards integrated aliases for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 15
Malignant Neoplasm of Bone Marrow 12 74
Myeloproliferative Disorder 41 17
Chronic Myeloproliferative Disorder 74
Myeloproliferative Disorders 45
Malignant Bone Marrow Tumor 12
Myeloproliferative Disease 74
Bone Marrow Neoplasms 74
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4960
MeSH 45 D009196
SNOMED-CT 69 20921005
ICD10 34 D47.1

Summaries for Bone Marrow Cancer

Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and juvenile myelomonocytic leukemia. An important gene associated with Bone Marrow Cancer is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydroxyurea and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Bone Marrow Cancer

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 33.4 ABL1 BCR FGFR1 JAK2 KIT MPL
2 juvenile myelomonocytic leukemia 32.7 FLT3 JAK2 PDGFRA PDGFRB PTPN11 STAT5A
3 thrombocythemia 1 32.3 MPL THPO
4 polycythemia vera 32.2 ABL1 CD177 EPO EPOR IL3 JAK2
5 myelodysplastic myeloproliferative cancer 32.2 ABL1 JAK2 PTPN11
6 erythroleukemia, familial 32.1 EPO EPOR GATA1
7 leukemia, chronic myeloid 31.9 ABL1 BCR CD177 CSF3 EPO FGFR1
8 myelofibrosis 31.7 CD177 CSF3 EPO FLT3 GATA1 IL3
9 leukemia 31.6 ABL1 BCR FLT3 JAK2 KIT MPL
10 thrombocytosis 31.5 EPO IL3 JAK2 MPL THPO
11 myelodysplastic syndrome 31.4 ABL1 CSF3 EPO EPOR FLT3 GATA1
12 megakaryocytic leukemia 31.1 GATA1 IL3 JAK2 THPO
13 mastocytosis 31.0 KIT PDGFRA PDGFRB
14 polycythemia 31.0 CD177 EPO EPOR IL3 JAK2 MPL
15 myeloid leukemia 31.0 ABL1 BCR FLT3 IL3 JAK2 KIT
16 splenomegaly 31.0 EPO JAK2 MPL
17 chronic myelomonocytic leukemia 30.8 FLT3 JAK2 KIT PDGFRB PTPN11
18 leukemia, acute lymphoblastic 30.7 ABL1 BCR FLT3 MIR155
19 acute leukemia 30.7 CSF3 FLT3 IL3 JAK2 KIT
20 thrombocytopenia 30.6 CSF3 GATA1 MPL THPO
21 hypereosinophilic syndrome 30.6 ABL1 FGFR1 IL3 KIT PDGFRA PDGFRB
22 systemic mastocytosis 30.5 FGFR1 JAK2 KIT PDGFRA PDGFRB
23 acquired polycythemia 30.5 EPO EPOR JAK2
24 essential thrombocythemia 30.3 ABL1 BCR CD177 EPO EPOR GATA1
25 pancytopenia 30.3 CSF3 EPO IL3 MPL THPO
26 myeloma, multiple 30.3 CSF3 EPO JAK2 KIT PTPN11
27 leukemia, acute myeloid 30.2 ABL1 BCR CSF3 FLT3 GATA1 IL3
28 lymphoma, non-hodgkin, familial 30.1 BCR CSF3 IL3 JAK2
29 aplastic anemia 30.1 CSF3 EPO FLT3 GATA1 IL3 MPL
30 myeloproliferative disorder, chronic, with eosinophilia 12.6
31 pdgfrb-associated chronic eosinophilic leukemia 11.7
32 noonan syndrome 1 11.3
33 erythromelalgia 11.3
34 campomelic dysplasia 11.1
35 mastocytosis, cutaneous 11.1
36 nodular regenerative hyperplasia 11.1
37 ocular cancer 11.0
38 papular mucinosis 11.0
39 erythermalgia, primary 10.9
40 thrombocythemia 2 10.9
41 noonan syndrome 3 10.9
42 noonan syndrome 4 10.9
43 noonan syndrome 5 10.9
44 noonan syndrome 6 10.9
45 chromosome 8p11 myeloproliferative syndrome 10.9
46 noonan syndrome 7 10.9
47 thrombocythemia 3 10.9
48 noonan syndrome 8 10.9
49 noonan syndrome 9 10.9
50 noonan syndrome 10 10.9

Graphical network of the top 20 diseases related to Bone Marrow Cancer:



Diseases related to Bone Marrow Cancer

Symptoms & Phenotypes for Bone Marrow Cancer

GenomeRNAi Phenotypes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

27 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.09 FLT3 PDGFRA
2 Decreased viability GR00221-A-1 10.09 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 10.09 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.09 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.09 FLT3 PDGFRA PDGFRB
6 Decreased viability GR00301-A 10.09 KIT
7 Decreased viability GR00342-S-1 10.09 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 10.09 ABL1
9 Decreased viability GR00342-S-3 10.09 ABL1
10 Decreased viability GR00402-S-2 10.09 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.89 ABL1 BCR FGFR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.89 ABL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.89 CSF3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.89 BCR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.89 BCR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.89 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.89 BCR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.89 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.89 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.89 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.89 ABL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.89 BCR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.89 BCR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.89 FGFR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.89 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.89 BCR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.89 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.89 BCR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.89 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.89 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.89 ABL1 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.89 CSF3
33 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.89 ABL1 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.89 FGFR1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.89 CSF3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.89 ABL1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.89 FGFR1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.89 ABL1 BCR CSF3 FGFR1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.89 ABL1 BCR
40 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
41 Decreased substrate adherent cell growth GR00193-A-2 9.7 ABL1 KIT
42 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT

MGI Mouse Phenotypes related to Bone Marrow Cancer:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 ABL1 BCR CD177 CSF3 EPO EPOR
2 cellular MP:0005384 10.38 ABL1 BCR EPO EPOR FGFR1 FLT3
3 immune system MP:0005387 10.33 ABL1 BCR CD177 CSF3 EPO EPOR
4 homeostasis/metabolism MP:0005376 10.31 ABL1 BCR EPO EPOR FGFR1 FLT3
5 growth/size/body region MP:0005378 10.29 ABL1 BCR EPOR FGFR1 FLT3 GATA1
6 embryo MP:0005380 10.25 ABL1 EPO EPOR FGFR1 GATA1 JAK2
7 endocrine/exocrine gland MP:0005379 10.15 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
8 mortality/aging MP:0010768 10.13 ABL1 BCR EPO EPOR FGFR1 FLT3
9 digestive/alimentary MP:0005381 10.07 ABL1 BCR FGFR1 KIT PDGFRA PDGFRB
10 integument MP:0010771 10.07 CSF3 EPO FGFR1 GATA1 JAK2 KIT
11 liver/biliary system MP:0005370 9.97 ABL1 BCR EPO EPOR GATA1 JAK2
12 normal MP:0002873 9.93 ABL1 BCR EPO EPOR FGFR1 GATA1
13 respiratory system MP:0005388 9.5 ABL1 EPO EPOR GATA1 KIT PDGFRA
14 skeleton MP:0005390 9.32 ABL1 EPO FGFR1 FLT3 GATA1 JAK2

Drugs & Therapeutics for Bone Marrow Cancer

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
2
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
3
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
4
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
5
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
6
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
7
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
8
Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
11
tannic acid Approved Phase 3,Phase 1,Phase 2 1401-55-4
12
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 94-09-7, 1994-09-7 2337
13
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 1,Phase 2 147-94-4, 65-46-3 6253
14
Melphalan Approved Phase 3,Phase 2,Not Applicable 148-82-3 460612 4053
15
Mercaptopurine Approved Phase 3 50-44-2 667490
16
Danazol Approved Phase 3 17230-88-5 28417
17
Proline Approved, Nutraceutical Phase 3,Phase 1,Phase 2 147-85-3 145742
18 interferons Phase 3,Phase 2,Phase 1
19 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
21 Interferon-alpha Phase 3,Phase 2,Phase 1
22 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
23 Interferon alpha-2 Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
25 Analgesics Phase 3,Phase 2,Phase 1
26 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
27 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
28 Platelet Aggregation Inhibitors Phase 3,Phase 2
29 Fibrinolytic Agents Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Cyclooxygenase Inhibitors Phase 3,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
34 Antipyretics Phase 3,Phase 2
35 Janus Kinase Inhibitors Phase 3,Phase 2
36 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
39 Mitogens Phase 3,Not Applicable
40 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3,Phase 2,Phase 1
41 Hormone Antagonists Phase 3,Phase 2
42 Antineoplastic Agents, Hormonal Phase 3,Phase 2
43 Antiemetics Phase 3,Phase 2
44 Gastrointestinal Agents Phase 3,Phase 2
45 glucocorticoids Phase 3,Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
47 Hormones Phase 3,Phase 2
48
protease inhibitors Phase 3,Phase 2
49 Autonomic Agents Phase 3,Phase 2
50 BB 1101 Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
2 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
3 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Completed NCT02292446 Phase 3 Ruxolitinib
4 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
5 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
6 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
7 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Completed NCT01243944 Phase 3 ruxolitinib tablets
8 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
9 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
10 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
11 The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation Recruiting NCT03640325 Phase 3
12 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Recruiting NCT03755518 Phase 3 FEDRATINIB
13 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
14 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Active, not recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
15 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
16 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
17 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
18 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Not yet recruiting NCT03859427 Phase 3 Carfilzomib;Carfilzomib;Lenalidomide;Dexamethasone
19 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
20 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
21 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
22 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
23 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
24 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
25 Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers Completed NCT00421213 Phase 2 Darinaparsin
26 The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) Completed NCT00436059 Phase 2 bortezomib
27 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
28 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
29 SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. Completed NCT00113893 Phase 2 SCIO-469;SCIO-469;SCIO-469;SCIO-469
30 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
31 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
32 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
33 Velcade Consolidation Bone Study Completed NCT01286077 Phase 2 bortezomib
34 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD Completed NCT00908232 Phase 2 Cyclophosphamide;Bortezomib;Dexamethasone;Lenalidomide
35 Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Completed NCT01745640 Phase 2 POMALIDOMIDE;Dexamethasone
36 Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Completed NCT00936117 Phase 2 Posaconazole
37 IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma Completed NCT01053949 Phase 2 Pomalidomide;Pomalidomide
38 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
39 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2 SAR302503
40 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
41 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
42 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)
43 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
44 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
45 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
46 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
47 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
48 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
49 Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Completed NCT01348490 Phase 2 Ruxolitinib (INCB018424)
50 Study of SB939 in Subjects With Myelofibrosis Completed NCT01200498 Phase 2 SB939

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: myeloproliferative disorders

Genetic Tests for Bone Marrow Cancer

Anatomical Context for Bone Marrow Cancer

MalaCards organs/tissues related to Bone Marrow Cancer:

42
Bone, Bone Marrow, Myeloid, Liver, T Cells, Testes, Breast

Publications for Bone Marrow Cancer

Articles related to Bone Marrow Cancer:

(show top 50) (show all 369)
# Title Authors Year
1
Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature. ( 30803277 )
2019
2
Death of a Fetus With Myeloproliferative Disorder and Trisomy 21. ( 30801117 )
2019
3
Role of monocyte chemoattractant protein-1 in liver fibrosis with transient myeloproliferative disorder in down syndrome. ( 29507898 )
2018
4
Sagittal sinus thrombosis in JAK2-V617F mutation without overt myeloproliferative disorder. ( 28228434 )
2017
5
Clinical implications of transient myeloproliferative disorder in a neonate without Down syndrome features. ( 28675575 )
2017
6
Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome. ( 28267084 )
2017
7
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. ( 28725653 )
2017
8
Acute febrile neutrophilic dermatosis associated with JAK-2 positive myeloproliferative disorder. ( 27118753 )
2016
9
Hemodynamic assessment of hydrops foetalis secondary to transient myeloproliferative disorder associated with foetal Down syndrome: A case report and literature review. ( 27612526 )
2016
10
Optical coherence tomographic findings of myeloproliferative disorder presenting as acute myocardial infarction. ( 26984860 )
2016
11
A Newborn with Down Syndrome, Developing Hydrops Fetalis Due to Transient Myeloproliferative Disorder and Liver Hamartoma. ( 29485829 )
2016
12
JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. ( 26458983 )
2016
13
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11. ( 26286251 )
2015
14
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. ( 26158763 )
2015
15
Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. ( 26205501 )
2015
16
Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder. ( 25736004 )
2015
17
Transient myeloproliferative disorder in neonates without Down syndrome: case report and review. ( 24853125 )
2015
18
Transient myeloproliferative disorder with partial trisomy 21. ( 26138905 )
2015
19
Loss of aryl hydrocarbon receptor promotes gene changes associated with premature hematopoietic stem cell exhaustion and development of a myeloproliferative disorder in aging mice. ( 24138668 )
2014
20
Mayo breakthrough: virus may destroy bone marrow cancer. ( 25233543 )
2014
21
Down syndrome with transient myeloproliferative disorder and Beta-thalassemia major. ( 25332579 )
2014
22
Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder. ( 25339837 )
2014
23
Transient myeloproliferative disorder and non-immune hydrops fetalis in a neonate with trisomy 21. ( 24473698 )
2014
24
Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a jak2 positive myeloproliferative disorder. ( 25386371 )
2014
25
Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia. ( 25555871 )
2014
26
Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy. ( 25248574 )
2014
27
Neonatal vesiculopustular eruption associated with transient myeloproliferative disorder: report of four cases. ( 23046498 )
2013
28
Runx3 deficiency results in myeloproliferative disorder in aged mice. ( 23741011 )
2013
29
The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report. ( 23599815 )
2013
30
Vesiculopustular eruption in neonate with trisomy 21 and transient myeloproliferative disorder. ( 23219445 )
2013
31
A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis. ( 23997080 )
2013
32
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder. ( 23675459 )
2013
33
Vesiculopustular Eruption in Neonatal Transient Myeloproliferative Disorder. ( 23949872 )
2013
34
Chemotherapy for transient myeloproliferative disorder in a premature infant with Down syndrome. ( 23510328 )
2013
35
Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. ( 23733339 )
2013
36
Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. ( 23719302 )
2013
37
Transient Myeloproliferative Disorder and Down Syndrome: Is there a link? ( 23275848 )
2012
38
The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. ( 22932805 )
2012
39
Skin involvement in a newborn with down syndrome and transient myeloproliferative disorder. ( 22469947 )
2012
40
Transient myeloproliferative disorder progression and acquired chromosomal abnormalities in children with Down syndrome. ( 22811256 )
2012
41
Transient myeloproliferative disorder in Down's syndrome. ( 23032858 )
2012
42
Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. ( 22473461 )
2012
43
Sonographic findings in a fatal case of transient myeloproliferative disorder. ( 22252957 )
2012
44
Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder. ( 19693645 )
2012
45
Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. ( 22701616 )
2012
46
Risk factors for early death in transient myeloproliferative disorder without phenotypic features of Down syndrome: a case report and literature review. ( 22510770 )
2012
47
Chronic myeloproliferative disorder with ETV6-PDGFRI^ fusion gene. ( 21833478 )
2012
48
Transient myeloproliferative disorder. ( 23350067 )
2012
49
Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder. ( 22966823 )
2012
50
Recurrence of severe low back pain due to myeloproliferative disorder in a patient affected by seronegative spondyloarthropathy. ( 21761195 )
2012

Variations for Bone Marrow Cancer

ClinVar genetic disease variations for Bone Marrow Cancer:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
3 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
4 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh38 Chromosome 4, 1804372: 1804372
5 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh37 Chromosome 9, 5078360: 5078360
6 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh38 Chromosome 9, 5078360: 5078360
7 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh37 Chromosome 5, 149441328: 149441328
8 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh38 Chromosome 5, 150061765: 150061765
9 FGFR3 NM_001163213.1(FGFR3): c.1663G> A (p.Val555Met) single nucleotide variant Uncertain significance rs199544087 GRCh37 Chromosome 4, 1807488: 1807488
10 FGFR3 NM_001163213.1(FGFR3): c.1663G> A (p.Val555Met) single nucleotide variant Uncertain significance rs199544087 GRCh38 Chromosome 4, 1805761: 1805761
11 INSL6; JAK2 NM_004972.3(JAK2): c.2624C> A (p.Thr875Asn) single nucleotide variant Likely pathogenic rs1057520016 GRCh38 Chromosome 9, 5089726: 5089726
12 INSL6; JAK2 NM_004972.3(JAK2): c.1691G> T (p.Arg564Leu) single nucleotide variant Likely pathogenic rs368927897 GRCh37 Chromosome 9, 5072541: 5072541
13 INSL6; JAK2 NM_004972.3(JAK2): c.1691G> T (p.Arg564Leu) single nucleotide variant Likely pathogenic rs368927897 GRCh38 Chromosome 9, 5072541: 5072541
14 INSL6; JAK2 NM_004972.3(JAK2): c.2624C> A (p.Thr875Asn) single nucleotide variant Likely pathogenic rs1057520016 GRCh37 Chromosome 9, 5089726: 5089726

Expression for Bone Marrow Cancer

Search GEO for disease gene expression data for Bone Marrow Cancer.

Pathways for Bone Marrow Cancer

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 ABL1 CD177 CSF3 FGFR1 FLT3 IL3
2
Show member pathways
13.89 ABL1 CSF3 EPOR FGFR1 FLT3 IL3
3
Show member pathways
13.75 BCR FGFR1 JAK2 KIT PDGFRA PDGFRB
4
Show member pathways
13.75 EPOR FGFR1 FLT3 IL3 JAK2 KIT
5
Show member pathways
13.7 CSF3 EPO EPOR FGFR1 FLT3 IL3
6
Show member pathways
13.59 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
7
Show member pathways
13.55 EPO EPOR FGFR1 FLT3 IL3 JAK2
8
Show member pathways
13.53 ABL1 FGFR1 IL3 JAK2 KIT PDGFRA
9
Show member pathways
13.45 CSF3 EPOR FGFR1 FLT3 IL3 JAK2
10
Show member pathways
13.39 CSF3 FGFR1 FLT3 IL3 JAK2 KIT
11
Show member pathways
13.35 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
12
Show member pathways
13.35 ABL1 CD177 GATA1 IL3 JAK2 MPL
13
Show member pathways
13.34 CSF3 FGFR1 IL3 JAK2 KIT PDGFRA
14
Show member pathways
13.31 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
15
Show member pathways
13.09 FGFR1 IL3 KIT PDGFRA PDGFRB THPO
16
Show member pathways
13.09 FGFR1 IL3 JAK2 KIT PDGFRA PDGFRB
17
Show member pathways
13.02 EPOR FGFR1 FLT3 KIT PDGFRA PDGFRB
18
Show member pathways
12.99 CSF3 EPO EPOR FGFR1 FLT3 IL3
19
Show member pathways
12.95 EPO EPOR JAK2 KIT PDGFRA PDGFRB
20
Show member pathways
12.88 EPOR FGFR1 JAK2 PDGFRA PDGFRB
21
Show member pathways
12.83 ABL1 EPO EPOR JAK2 STAT5A
22
Show member pathways
12.81 ABL1 BCR FGFR1 FLT3 IL3 KIT
23
Show member pathways
12.8 JAK2 MPL PTPN11 STAT5A THPO
24 12.79 FGFR1 FLT3 KIT PDGFRA PDGFRB
25
Show member pathways
12.78 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
26
Show member pathways
12.76 FGFR1 KIT PDGFRA PDGFRB PTPN11
27
Show member pathways
12.72 FGFR1 JAK2 PDGFRA PDGFRB STAT5A
28 12.63 GATA1 IL3 JAK2 KIT MPL STAT5A
29
Show member pathways
12.62 JAK2 PDGFRA PDGFRB PTPN11 STAT5A
30 12.52 ABL1 MIR155 PDGFRA PDGFRB
31 12.46 ABL1 BCR EPO EPOR FGFR1 FLT3
32
Show member pathways
12.45 FGFR1 FLT3 PTPN11 STAT5A
33
Show member pathways
12.43 KIT PDGFRA PDGFRB PTPN11
34
Show member pathways
12.43 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
35
Show member pathways
12.36 FLT3 IL3 JAK2 STAT5A
36
Show member pathways
12.32 ABL1 FGFR1 IL3 KIT PDGFRA PDGFRB
37 12.22 ABL1 JAK2 PTPN11 STAT5A
38
Show member pathways
12.2 BCR FGFR1 STAT5A ZMYM2
39
Show member pathways
12.18 EPO EPOR IL3 JAK2 KIT PTPN11
40
Show member pathways
12.12 FGFR1 IL3 JAK2 PTPN11 THPO
41 12.1 GATA1 IL3 PDGFRB THPO
42
Show member pathways
12 IL3 JAK2 PTPN11 STAT5A
43 11.98 JAK2 MPL PTPN11 STAT5A THPO
44
Show member pathways
11.98 EPO EPOR JAK2 PTPN11 STAT5A
45 11.93 CSF3 EPO FLT3 IL3 KIT MPL
46 11.93 ABL1 BCR FGFR1 FLT3 JAK2 KIT
47
Show member pathways
11.91 BCR FGFR1 STAT5A ZMYM2
48 11.89 ABL1 EPO EPOR IL3 JAK2 PTPN11
49
Show member pathways
11.87 FGFR1 FLT3 KIT PDGFRB
50 11.86 FGFR1 PDGFRA PDGFRB

GO Terms for Bone Marrow Cancer

Cellular components related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 EPOR FGFR1 FLT3 KIT MPL PDGFRA
2 receptor complex GO:0043235 9.02 FGFR1 FLT3 KIT PDGFRA PDGFRB

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.98 BCR EPOR FGFR1 PTPN11
2 positive regulation of cell migration GO:0030335 9.98 JAK2 KIT PDGFRA PDGFRB
3 positive regulation of MAPK cascade GO:0043410 9.98 FGFR1 FLT3 KIT PDGFRA PDGFRB
4 positive regulation of protein kinase B signaling GO:0051897 9.98 CSF3 FGFR1 KIT PDGFRA PDGFRB PTPN11
5 phosphatidylinositol phosphorylation GO:0046854 9.96 FGFR1 KIT PDGFRA PDGFRB PTPN11
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 ABL1 CSF3 GATA1 IL3 JAK2
7 protein autophosphorylation GO:0046777 9.92 ABL1 BCR FGFR1 FLT3 JAK2 KIT
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.91 FLT3 KIT PDGFRA PDGFRB
9 positive regulation of MAP kinase activity GO:0043406 9.89 FGFR1 FLT3 KIT PDGFRB
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 EPO FLT3 IL3 JAK2 KIT
11 male gonad development GO:0008584 9.88 GATA1 KIT PDGFRB
12 erythrocyte differentiation GO:0030218 9.88 EPO GATA1 JAK2 KIT
13 cell chemotaxis GO:0060326 9.86 KIT PDGFRA PDGFRB
14 cellular response to cytokine stimulus GO:0071345 9.84 CSF3 FLT3 PTPN11
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.84 FLT3 KIT PDGFRA PDGFRB
16 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.83 FGFR1 FLT3 PTPN11
17 positive regulation of fibroblast proliferation GO:0048146 9.83 MIR155 PDGFRA PDGFRB
18 phosphatidylinositol-mediated signaling GO:0048015 9.82 FGFR1 PDGFRA PDGFRB
19 platelet aggregation GO:0070527 9.82 GATA1 MPL PDGFRA
20 cell differentiation GO:0030154 9.81 ABL1 FLT3 JAK2
21 embryonic hemopoiesis GO:0035162 9.78 GATA1 IL3 KIT
22 positive regulation of phospholipase C activity GO:0010863 9.78 FGFR1 KIT PDGFRA PDGFRB
23 negative regulation of apoptotic process GO:0043066 9.77 EPO GATA1 PDGFRB
24 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 ABL1 EPO FLT3 KIT PDGFRA PDGFRB
25 platelet-derived growth factor receptor signaling pathway GO:0048008 9.73 ABL1 BCR JAK2 PDGFRA PDGFRB PTPN11
26 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.7 JAK2 PDGFRB
27 interleukin-6-mediated signaling pathway GO:0070102 9.7 JAK2 PTPN11
28 megakaryocyte development GO:0035855 9.7 KIT PTPN11
29 negative regulation of cell-cell adhesion GO:0022408 9.7 ABL1 JAK2
30 cellular response to thyroid hormone stimulus GO:0097067 9.69 GATA1 KIT
31 response to hyperoxia GO:0055093 9.69 EPO PDGFRB
32 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.69 JAK2 STAT5A
33 erythropoietin-mediated signaling pathway GO:0038162 9.69 EPO EPOR KIT
34 dendritic cell differentiation GO:0097028 9.68 FLT3 GATA1
35 positive regulation of osteoblast proliferation GO:0033690 9.67 ABL1 GATA1
36 Bergmann glial cell differentiation GO:0060020 9.67 ABL1 PTPN11
37 retina vasculature development in camera-type eye GO:0061298 9.67 PDGFRA PDGFRB
38 myeloid progenitor cell differentiation GO:0002318 9.66 FLT3 KIT
39 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.63 ABL1 PDGFRB
40 thrombopoietin-mediated signaling pathway GO:0038163 9.63 MPL THPO
41 metanephric glomerular capillary formation GO:0072277 9.62 PDGFRA PDGFRB
42 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.62 PDGFRA PDGFRB
43 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.5 CSF3 FGFR1 FLT3 JAK2 KIT PDGFRA
44 peptidyl-tyrosine phosphorylation GO:0018108 9.36 ABL1 BCR FGFR1 FLT3 IL3 JAK2
45 phosphorylation GO:0016310 10.17 ABL1 BCR FGFR1 FLT3 JAK2 KIT
46 protein phosphorylation GO:0006468 10.15 ABL1 BCR FGFR1 FLT3 JAK2 KIT
47 positive regulation of cell proliferation GO:0008284 10.1 CSF3 EPO FGFR1 FLT3 IL3 JAK2
48 cytokine-mediated signaling pathway GO:0019221 10.02 CSF3 EPOR FLT3 IL3 JAK2 KIT
49 MAPK cascade GO:0000165 10 FGFR1 FLT3 IL3 JAK2 KIT PDGFRA

Molecular functions related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.97 ABL1 BCR FGFR1 FLT3 JAK2 KIT
2 protein kinase activity GO:0004672 9.95 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
3 nucleotide binding GO:0000166 9.91 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
4 cytokine activity GO:0005125 9.84 CSF3 EPO IL3 THPO
5 1-phosphatidylinositol-3-kinase activity GO:0016303 9.65 FGFR1 FLT3 PTPN11
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.65 FGFR1 KIT PDGFRA PDGFRB PTPN11
7 cytokine receptor activity GO:0004896 9.63 EPOR FLT3 MPL
8 platelet-derived growth factor receptor binding GO:0005161 9.58 PDGFRA PDGFRB
9 insulin receptor substrate binding GO:0043560 9.58 JAK2 PTPN11
10 platelet-derived growth factor binding GO:0048407 9.57 PDGFRA PDGFRB
11 peptide hormone receptor binding GO:0051428 9.55 JAK2 PTPN11
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.55 FGFR1 FLT3 KIT PDGFRA PDGFRB
13 vascular endothelial growth factor-activated receptor activity GO:0005021 9.52 FLT3 PDGFRA
14 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 FGFR1 FLT3 IL3 JAK2 KIT PDGFRA
15 vascular endothelial growth factor binding GO:0038085 9.49 PDGFRA PDGFRB
16 protein tyrosine kinase activity GO:0004713 9.36 ABL1 BCR FGFR1 FLT3 IL3 JAK2
17 transmembrane signaling receptor activity GO:0004888 9.02 MPL
18 transferase activity GO:0016740 10.16 ABL1 BCR FGFR1 FLT3 JAK2 KIT
19 ATP binding GO:0005524 10.11 ABL1 BCR FGFR1 FLT3 JAK2 KIT

Sources for Bone Marrow Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....